Logo image of NGEN.CA

NERVGEN PHARMA CORP (NGEN.CA) Stock Fundamental Analysis

TSX-V:NGEN - CA64082X2032 - Common Stock

3.71 CAD
+0.39 (+11.75%)
Last: 8/28/2025, 7:00:00 PM
Fundamental Rating

2

Overall NGEN gets a fundamental rating of 2 out of 10. We evaluated NGEN against 34 industry peers in the Pharmaceuticals industry. The financial health of NGEN is average, but there are quite some concerns on its profitability. NGEN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NGEN has reported negative net income.
NGEN had a negative operating cash flow in the past year.
In the past 5 years NGEN always reported negative net income.
In the past 5 years NGEN always reported negative operating cash flow.
NGEN.CA Yearly Net Income VS EBIT VS OCF VS FCFNGEN.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of NGEN (-161.68%) is worse than 91.18% of its industry peers.
NGEN has a worse Return On Equity (-1843.02%) than 88.24% of its industry peers.
Industry RankSector Rank
ROA -161.68%
ROE -1843.02%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NGEN.CA Yearly ROA, ROE, ROICNGEN.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

NGEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NGEN.CA Yearly Profit, Operating, Gross MarginsNGEN.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

There is no outstanding debt for NGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NGEN.CA Yearly Shares OutstandingNGEN.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
NGEN.CA Yearly Total Debt VS Total AssetsNGEN.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -1.25, we must say that NGEN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.25, NGEN is doing worse than 64.71% of the companies in the same industry.
NGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.25
ROIC/WACCN/A
WACCN/A
NGEN.CA Yearly LT Debt VS Equity VS FCFNGEN.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

NGEN has a Current Ratio of 1.06. This is a normal value and indicates that NGEN is financially healthy and should not expect problems in meeting its short term obligations.
NGEN has a worse Current ratio (1.06) than 76.47% of its industry peers.
NGEN has a Quick Ratio of 1.06. This is a normal value and indicates that NGEN is financially healthy and should not expect problems in meeting its short term obligations.
NGEN has a Quick ratio of 1.06. This is comparable to the rest of the industry: NGEN outperforms 44.12% of its industry peers.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 1.06
NGEN.CA Yearly Current Assets VS Current LiabilitesNGEN.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.54% over the past year.
EPS 1Y (TTM)5.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 46.51% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.85%
EPS Next 2Y24.03%
EPS Next 3Y12.47%
EPS Next 5Y46.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NGEN.CA Yearly Revenue VS EstimatesNGEN.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 200M 400M 600M
NGEN.CA Yearly EPS VS EstimatesNGEN.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGEN.CA Price Earnings VS Forward Price EarningsNGEN.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGEN.CA Per share dataNGEN.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3

4.3 Compensation for Growth

A more expensive valuation may be justified as NGEN's earnings are expected to grow with 12.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.03%
EPS Next 3Y12.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NGEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NERVGEN PHARMA CORP

TSX-V:NGEN (8/28/2025, 7:00:00 PM)

3.71

+0.39 (+11.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-22 2025-08-22
Earnings (Next)11-12 2025-11-12
Inst Owners0.06%
Inst Owner ChangeN/A
Ins Owners2.36%
Ins Owner ChangeN/A
Market Cap271.13M
Analysts80
Price Target9 (142.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.72%
Min EPS beat(2)-51.43%
Max EPS beat(2)33.99%
EPS beat(4)2
Avg EPS beat(4)-3.86%
Min EPS beat(4)-51.43%
Max EPS beat(4)33.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)77.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)37.5%
EPS NY rev (1m)18.87%
EPS NY rev (3m)18.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 195.13
P/tB 288.89
EV/EBITDA N/A
EPS(TTM)-0.39
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0
BVpS0.02
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -161.68%
ROE -1843.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.06
Quick Ratio 1.06
Altman-Z -1.25
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)38.62%
Cap/Depr(5y)46.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-18.18%
EPS Next Y2.85%
EPS Next 2Y24.03%
EPS Next 3Y12.47%
EPS Next 5Y46.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.72%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.41%
OCF growth 3YN/A
OCF growth 5YN/A